1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsGilead Sciences: Corporate Giving in Europe is sponsored by Gilead Sciences. Supports projects in Europe and the Middle East across therapeutic areas including HIV, liver diseases, hematology and oncology, and inflammatory and respiratory diseases.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Gilead Sciences: How to Apply for Grant Funding We partner with patient advocates, nonprofits, and healthcare professionals across our core therapeutic areas to improve care through community engagement. By supporting community-informed, data-driven programs, we help strengthen healthcare infrastructure, expand education and provide financial support to the most vulnerable populations.
Our corporate giving focuses on where the need is greatest, prioritizing initiatives with a clear ability to deliver meaningful outcomes. Patient Community Support We strive to advance health equity, diversity in clinical trials and access to medicines to reduce disparities. We also support the local communities in which we operate.
We welcome funding requests for innovative, high-impact projects that relate to at least one of our core therapeutic areas: Primary biliary cholangitis Chronic Inflammatory Diseases Many individuals face barriers to accessing healthcare due to age, disability, ethnicity or race, location, gender, gender identity or socioeconomic status.
To help ensure all people have the opportunity to get the best possible care – regardless of background – Gilead sponsors select events or conferences that raise awareness and support organizations working in our therapeutic areas of focus. Please see our sponsorships FAQ for more information .
We work with patient advocates, nonprofits, and healthcare professionals across all our therapeutic areas of focus to improve care through partnerships and community engagement. Latin America & the Caribbean
According to the current listing, eligibility includes: Organizations in eligible European and Middle Eastern countries working in the specified therapeutic areas. Confirm the full requirements in the official notice before applying.
Gilead Sciences: Corporate Giving in Europe is funded by Gilead Sciences. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read articleSchmidt Sciences opened a 'Scaling AI Safety for a Multi-Agent World' program with awards up to $1 million and an August 8, 2026 deadline. Against a backdrop of federal research slowdowns, here is why private science philanthropy matters more than ever, how these funders differ from federal agencies, and how researchers should approach them.
Read articleNSF's Arctic Research Opportunities solicitation funds roughly 75 awards a year — up to $50 million — across six program areas from natural sciences to social sciences to the Arctic Observing Network. The July 15, 2026 target date is not a hard deadline, and understanding that distinction is the first strategic decision an Arctic researcher makes. Here is how the six doors differ and how to choose the right one.
Read article